var data={"title":"Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/contributors\" class=\"contributor contributor_credentials\">Igor J Koralnik, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/contributors\" class=\"contributor contributor_credentials\">Francisco Gonz&aacute;lez-Scarano, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/contributors\" class=\"contributor contributor_credentials\">John F Dashe, MD, PhD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Apr 28, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Progressive multifocal leukoencephalopathy (PML) is a severe demyelinating disease of the central nervous system that is caused by reactivation of the polyomavirus JC (JC virus) [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/1-3\" class=\"abstract_t\">1-3</a>]. Asymptomatic primary infection with JC virus occurs in childhood and antibodies can be found in 86 percent of adults [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/4\" class=\"abstract_t\">4</a>]. In most individuals, JC virus remains latent in kidneys and lymphoid organs, but, in the context of profound cellular immunosuppression, JC virus can reactivate, spread to the brain, and induce a lytic infection of oligodendrocytes, which are the CNS myelin-producing cells. (See <a href=\"topic.htm?path=virology-epidemiology-and-pathogenesis-of-jc-polyomavirus-bk-polyomavirus-and-other-human-polyomaviruses\" class=\"medical medical_review\">&quot;Virology, epidemiology, and pathogenesis of JC polyomavirus, BK polyomavirus, and other human polyomaviruses&quot;</a>.)</p><p>The epidemiology, clinical features, and diagnosis of PML will be reviewed here. The treatment of PML is discussed separately. (See <a href=\"topic.htm?path=progressive-multifocal-leukoencephalopathy-treatment-and-prognosis\" class=\"medical medical_review\">&quot;Progressive multifocal leukoencephalopathy: Treatment and prognosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Progressive multifocal leukoencephalopathy (PML) occurs almost exclusively in immunosuppressed individuals. There are only isolated case reports of PML in patients without apparent immunosuppression [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/5-9\" class=\"abstract_t\">5-9</a>]. There are, however, reports of PML affecting patients who have conditions associated with minimal or occult immunosuppression, such as hepatic cirrhosis and renal failure [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/10\" class=\"abstract_t\">10</a>].</p><p>PML was initially described in patients with lymphoproliferative and myeloproliferative diseases such as chronic lymphocytic leukemia, chronic myeloid leukemia, and Hodgkin lymphoma [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/11-16\" class=\"abstract_t\">11-16</a>]. It was subsequently reported in rare patients with solid organ malignancies, granulomatous and inflammatory diseases, solid organ transplant recipients, and with the use of certain drugs. Rare cases of PML have been observed in CD8-positive T-cell leukopenic patients [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/17\" class=\"abstract_t\">17</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The prevalence of PML was estimated to be 0.07 percent among patients with hematologic malignancies [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/18\" class=\"abstract_t\">18</a>] and 0.8 percent in a retrospective autopsy study of liver transplant recipients [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/19\" class=\"abstract_t\">19</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Another report reviewed 427 cases of heart or lung transplant recipients and identified 3 cases of PML, with a calculated incidence rate of 1.2 cases per 1000 post-transplantation years [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/20\" class=\"abstract_t\">20</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a retrospective population-based study that analyzed a health insurance database, the incidence rates of PML in patients with systemic lupus erythematosus, autoimmune vasculitis, non-Hodgkin lymphoma, chronic lymphocytic leukemia, and bone marrow transplantation were 2.4, 10.8, 8.3, 11.1, and 35.4 per 100,000 person-years [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/21\" class=\"abstract_t\">21</a>]. There were no PML cases among patients with rheumatoid arthritis, multiple sclerosis, Sj&ouml;gren disease, or solid organ transplantation. However, the confidence intervals around the incidence rates for these groups with and without PML cases were wide and overlapping. Thus, the group differences in the incidence of PML were <strong>not</strong> statistically significant.</p><p/><p>Prior to the widespread use of combined antiretroviral therapy (ART) in the United States and Europe, PML was recognized as a major opportunistic infection associated with AIDS in adults, with a prevalence of 1 to 5 percent [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/18,22-24\" class=\"abstract_t\">18,22-24</a>]. In a review of 61 patients with PML seen between 1995 and 2004, 79 percent had AIDS, 13 percent had hematologic malignancies, 5 percent were bone marrow transplant recipients, and one patient each had thymoma and dermatomyositis [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/25\" class=\"abstract_t\">25</a>]. PML has also been described in HIV-infected children [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/26-28\" class=\"abstract_t\">26-28</a>], at an estimated rate of 0.06 per 100 person-years prior to combined ART [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/28\" class=\"abstract_t\">28</a>], and in HIV-negative patients with idiopathic CD4+ lymphocytopenia [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/29\" class=\"abstract_t\">29</a>]. (See <a href=\"topic.htm?path=idiopathic-cd4-lymphocytopenia#H18\" class=\"medical medical_review\">&quot;Idiopathic CD4+ lymphocytopenia&quot;, section on 'Other opportunistic infections'</a>.)</p><p>Since the widespread use of combined ART, the incidence of PML in patients with HIV infection has decreased [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/30,31\" class=\"abstract_t\">30,31</a>]. In a population-based study from Denmark involving a nationwide cohort of patients aged 16 and older with HIV infection, the incidence of PML declined over three observation periods as follows [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/31\" class=\"abstract_t\">31</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>1995 to 1996 (pre-ART): 3.3 <span class=\"nowrap\">cases/1000</span> patient-years at risk [PYR] (95% CI 1.9-5.7)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>1997 to 1999 (early ART): 1.8 <span class=\"nowrap\">cases/1000</span> PYR (95% CI 1.0-3.2)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>2000 to 2006 (late ART): 1.3 <span class=\"nowrap\">cases/1000</span> PYR (95% CI 0.8-1.9)</p><p/><p>In addition, PML may improve or stabilize with potent antiretroviral therapy, leading to prolonged survival. This issue is discussed separately. (See <a href=\"topic.htm?path=progressive-multifocal-leukoencephalopathy-treatment-and-prognosis#H4\" class=\"medical medical_review\">&quot;Progressive multifocal leukoencephalopathy: Treatment and prognosis&quot;, section on 'HIV infection'</a>.)</p><p>In contrast to the above findings from the United States and Europe, PML has been rarely reported in HIV-infected patients in India and Africa. The reason for this phenomenon is not clear, but nonrecognition, lack of simple diagnostic tests, underreporting, premature deaths due to other infections, potential interactions between JC virus and different HIV clades, or host genetic differences may be implicated [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/32\" class=\"abstract_t\">32</a>]. However, a study of 331 HIV-infected patients presenting with central nervous system opportunistic infection in Zambia detected JCV DNA by polymerase chain reaction in 6 percent of cerebrospinal fluid samples, suggesting that PML indeed occurs in Africa [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/33\" class=\"abstract_t\">33</a>]. </p><p class=\"headingAnchor\" id=\"H3055033646\"><span class=\"h2\">Immunomodulatory drugs and PML</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is an increased risk of PML associated with the use of <a href=\"topic.htm?path=natalizumab-drug-information\" class=\"drug drug_general\">natalizumab</a>, an immunomodulatory drug that prevents normal trafficking of leukocytes by binding to integrin receptors. Natalizumab is primarily used to treat patients with relapsing-remitting multiple sclerosis and select patients with Crohn disease. These associations are described in detail elsewhere. (See <a href=\"topic.htm?path=natalizumab-for-relapsing-remitting-multiple-sclerosis-in-adults#H4\" class=\"medical medical_review\">&quot;Natalizumab for relapsing-remitting multiple sclerosis in adults&quot;, section on 'Risk of PML'</a> and <a href=\"topic.htm?path=natalizumab-for-treatment-of-crohn-disease-in-adults#H4\" class=\"medical medical_review\">&quot;Natalizumab for treatment of Crohn disease in adults&quot;, section on 'Adverse events'</a>.)</p><p>PML has also been reported occasionally in patients treated with other immunomodulatory drugs, including: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=belatacept-drug-information\" class=\"drug drug_general\">Belatacept</a> [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/34,35\" class=\"abstract_t\">34,35</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Brentuximab [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/36\" class=\"abstract_t\">36</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=eculizumab-drug-information\" class=\"drug drug_general\">Eculizumab</a> [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/37\" class=\"abstract_t\">37</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Efalizumab [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/38,39\" class=\"abstract_t\">38,39</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=fludarabine-drug-information\" class=\"drug drug_general\">Fludarabine</a> [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/12-16\" class=\"abstract_t\">12-16</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Glucocorticoids [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/40\" class=\"abstract_t\">40</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ibrutinib-drug-information\" class=\"drug drug_general\">Ibrutinib</a> [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/41,42\" class=\"abstract_t\">41,42</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=idelalisib-drug-information\" class=\"drug drug_general\">Idelalisib</a> [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/41\" class=\"abstract_t\">41</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-drug-information\" class=\"drug drug_general\">Infliximab</a> [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/43\" class=\"abstract_t\">43</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information\" class=\"drug drug_general\">Mycophenolate</a> [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/44-46\" class=\"abstract_t\">44-46</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=obinutuzumab-drug-information\" class=\"drug drug_general\">Obinutuzumab</a> [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/41\" class=\"abstract_t\">41</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ofatumumab-drug-information\" class=\"drug drug_general\">Ofatumumab</a> [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/41\" class=\"abstract_t\">41</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">Rituximab</a> [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/47-49\" class=\"abstract_t\">47-49</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ruxolitinib-drug-information\" class=\"drug drug_general\">Ruxolitinib</a> [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/50\" class=\"abstract_t\">50</a>]</p><p/><p>In some cases, these drugs were used in combination with other immunosuppressive medications (eg, <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a>, <a href=\"topic.htm?path=leflunomide-drug-information\" class=\"drug drug_general\">leflunomide</a>, <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a>) [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/43,51\" class=\"abstract_t\">43,51</a>]. Many of the patients had an underlying hematologic malignancy or collagen vascular disease.</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>As the name implies, classic progressive multifocal leukoencephalopathy (PML) is progressive, multifocal, and involves the white matter. However, atypical presentations are increasingly recognized. Since PML can also present as a single lesion, may not always be progressive, and may involve the gray matter, the term PML may be misleading for clinicians confronted with the non-classic form of this disease [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/11\" class=\"abstract_t\">11</a>]. JC virus encephalopathy may better encompass all disease manifestations.</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Classic PML</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>PML usually manifests with subacute neurologic deficits including altered mental status, motor deficits (hemiparesis or monoparesis), limb ataxia, gait ataxia, and visual symptoms such as hemianopia and diplopia. Most patients with HIV infection and PML are profoundly immunosuppressed with CD4-positive T-cell counts &lt;200 per mm<sup>3</sup>. Initial symptoms may vary greatly from patient to patient, depending on the location of their lesions in the central nervous system white matter. PML typically spares the optic nerves and the spinal cord, although incidental finding of PML lesions in the spinal cord has been reported in the postmortem examination of one patient with HIV infection who died from hemispheric PML [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/52\" class=\"abstract_t\">52</a>].</p><p>Although PML lesions are located mainly in the white matter, PML symptoms are frequently indicative of a cortical disorder. These cortical symptoms have been attributed to white matter lesions that undercut relevant cortical areas. As examples, aphasia may result from lesions underlying the language areas in the left frontal and temporal lobes, and lesions in the occipital lobe white matter can mimic symptoms of cortical blindness. However, neuropathologic study has revealed that cortical demyelination is a frequent finding with PML, suggesting that cortical symptoms in PML may arise from cortical demyelinating lesions. (See <a href=\"#H6\" class=\"local\">'Neuropathology'</a> below.)</p><p>Seizures are usually thought to be a manifestation of cortical injury rather than white matter disease. Nonetheless, seizures occur in up to 44 percent of patients who survive PML, mainly when PML lesions are located immediately adjacent to the cortex [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/53,54\" class=\"abstract_t\">53,54</a>].</p><p>The disease course of PML is usually progressive and fatal. The median survival of patients without HIV infection is only a few months. Survival in the era of highly active antiretroviral therapy is longer, but survivors are often left with severe neurologic sequelae. This is discussed separately. (See <a href=\"topic.htm?path=progressive-multifocal-leukoencephalopathy-treatment-and-prognosis#H56322198\" class=\"medical medical_review\">&quot;Progressive multifocal leukoencephalopathy: Treatment and prognosis&quot;, section on 'Natural history and prognosis'</a>.)</p><p class=\"headingAnchor\" id=\"H60052309\"><span class=\"h3\">Neuroimaging</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The typical appearance of PML on neuroimaging studies consists of symmetric or asymmetric multifocal areas of white matter demyelination that do not conform to cerebrovascular territories and exhibit neither mass effect nor contrast enhancement.</p><p>On cranial CT, PML lesions can appear as hypodense patchy or confluent white matter regions [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/55\" class=\"abstract_t\">55</a>]. On MRI, the lesions of PML are seen as areas of decreased signal on T1-weighted images and increased signal on T2-weighted and fluid attenuated inversion recovery (FLAIR) sequences (<a href=\"image.htm?imageKey=NEURO%2F72702\" class=\"graphic graphic_diagnosticimage graphicRef72702 \">image 1</a>) [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/55-57\" class=\"abstract_t\">55-57</a>]. In addition, PML lesions may be hyperintense on diffusion-weighted sequences (<a href=\"image.htm?imageKey=NEURO%2F65187\" class=\"graphic graphic_diagnosticimage graphicRef65187 \">image 2</a>) [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/58,59\" class=\"abstract_t\">58,59</a>]. PML lesions are usually bilateral and localized preferentially to the periventricular areas and the subcortical white matter, and may involve the corpus callosum, brainstem, pyramidal tracts, and cerebellum [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/55-57\" class=\"abstract_t\">55-57</a>]. Involvement of the deep gray structures, including basal ganglia and thalamus, can be found in up to 17 percent of cases; this is always in conjunction with white matter disease (<a href=\"image.htm?imageKey=NEURO%2F65187\" class=\"graphic graphic_diagnosticimage graphicRef65187 \">image 2</a>) [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/60\" class=\"abstract_t\">60</a>]. Of note, cortical demyelination in PML is not discernible with conventional MRI [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/61\" class=\"abstract_t\">61</a>]. (See <a href=\"#H6\" class=\"local\">'Neuropathology'</a> below.)</p><p>The lesions of PML generally do not enhance with contrast or develop surrounding edema [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/60\" class=\"abstract_t\">60</a>]. As a result, substantial mass effect on adjacent structures is usually absent [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/60\" class=\"abstract_t\">60</a>]. However, atypical enhancing PML lesions, biopsy-proven, have been described on neuroimaging studies. These unusual radiologic findings have been observed most often in patients with HIV infection who initiated combined antiretroviral therapy (ART) and then became neurologically symptomatic from PML disease [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/62-64\" class=\"abstract_t\">62-64</a>]. They also have been found in patients without HIV infection, including some with natalizumab-associated PML [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/65,66\" class=\"abstract_t\">65,66</a>]. These atypical inflammatory lesions may become more common as the presentation of PML is altered by immune reconstitution with antiretroviral therapy [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/62\" class=\"abstract_t\">62</a>]. (See <a href=\"#H7\" class=\"local\">'Inflammatory PML'</a> below and <a href=\"topic.htm?path=immune-reconstitution-inflammatory-syndrome\" class=\"medical medical_review\">&quot;Immune reconstitution inflammatory syndrome&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h3\">Neuropathology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Early neuropathologic studies of PML found demyelination only involving the subcortical white matter. However, later reports have shown that JC virus causes infection of cortical neurons and that demyelinating lesions of PML frequently involve gray matter [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/67,68\" class=\"abstract_t\">67,68</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>One study examined autopsy brain tissue from 13 patients with PML and HIV infection found cortical demyelinating lesions in all 13 [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/67\" class=\"abstract_t\">67</a>]. Two types of demyelinating lesions were detected in these patients:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Leukocortical lesions extended to the cortex from underlying white matter and accounted for the highest percentage of demyelination in PML brains</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Intracortical lesions were located entirely within the cortex and were typically small (0.03 to 0.6 mm<sup>3</sup>) and numerous</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In another report that looked at neuropathologic tissue from 49 patients with PML, demyelinating lesions were present in the white matter and gray-white junction in 96 percent and in the gray matter in 57 percent of patients [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/68\" class=\"abstract_t\">68</a>]. While most of the cells infected with JC virus were glial, JC virus infection of neurons was found in approximately one-half of patients. In addition, JC virus infection of gray matter neurons located outside of demyelinating lesions was present in 11 percent of patients.</p><p/><p>Thus, it is now recognized that PML-associated demyelination affects both the cortex and subcortical white matter.</p><p>The histopathologic features of PML (<a href=\"image.htm?imageKey=NEURO%2F90142\" class=\"graphic graphic_figure graphicRef90142 \">figure 1</a>) are described below. (See <a href=\"#H117387201\" class=\"local\">'Brain biopsy'</a> below.)</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Inflammatory PML</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although ART has improved the clinical outcome of patients with HIV infection who have PML, it has also been associated with new onset or clinical worsening of PML. This occurs mainly in patients who display a marked increase in CD4-positive T-cell counts and a decrease in HIV plasma viral load, indicating a recovery of the immune system. This paradoxical development of PML is usually accompanied by an inflammatory reaction in PML lesions known as the immune reconstitution inflammatory syndrome (IRIS) and demonstrated by contrast enhancement on brain MRI. (See <a href=\"topic.htm?path=immune-reconstitution-inflammatory-syndrome\" class=\"medical medical_review\">&quot;Immune reconstitution inflammatory syndrome&quot;</a>.)</p><p>The co-occurrence of IRIS with PML has been observed also in patients with multiple sclerosis treated with <a href=\"topic.htm?path=natalizumab-drug-information\" class=\"drug drug_general\">natalizumab</a> [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/69-71\" class=\"abstract_t\">69-71</a>]. (See <a href=\"topic.htm?path=natalizumab-for-relapsing-remitting-multiple-sclerosis-in-adults#H4\" class=\"medical medical_review\">&quot;Natalizumab for relapsing-remitting multiple sclerosis in adults&quot;, section on 'Risk of PML'</a> and <a href=\"topic.htm?path=progressive-multifocal-leukoencephalopathy-treatment-and-prognosis#H56321583\" class=\"medical medical_review\">&quot;Progressive multifocal leukoencephalopathy: Treatment and prognosis&quot;, section on 'Natalizumab-associated PML'</a>.)</p><p>Despite the initial worsening, observational studies suggest that the clinical outcome from inflammatory PML is generally more favorable than classic PML [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/62\" class=\"abstract_t\">62</a>], although some cases are fatal [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/72\" class=\"abstract_t\">72</a>]. In a retrospective review with data for 54 patients with PML and IRIS, the mortality rate was 35 percent [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/73\" class=\"abstract_t\">73</a>].</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">JC virus cerebellar granule cell neuronopathy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In addition to PML, JC virus may cause a productive and lytic infection of cerebellar granule cell neurons, leading to ataxia and cerebellar atrophy [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/74,75\" class=\"abstract_t\">74,75</a>]. This novel syndrome has been named JC virus granule cell neuronopathy (JCV GCN).</p><p>The data indicate that JC virus, at least in certain individuals, is also capable of infecting neurons, and not only glial cells [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/74,75\" class=\"abstract_t\">74,75</a>]. In a study examining brain tissue (nearly all derived from autopsy) from patients with PML, JC virus infection of granule cell neurons was detected in 15 of 19 tested samples (79 percent), including some cases without PML lesions in the nearby cerebellar white mater (<a href=\"image.htm?imageKey=NEURO%2F67660\" class=\"graphic graphic_figure graphicRef67660 \">figure 2</a>) [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/76\" class=\"abstract_t\">76</a>]. Mutations in the structure of the JC virus VP1 capsid protein have been identified in a few patients with JCV GCN, suggesting that VP1 protein mutations are important to the pathogenesis of GCN [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/77,78\" class=\"abstract_t\">77,78</a>].</p><p>JC virus GCN should be differentiated from the cerebellar syndrome which is frequently found in PML when lesions occur in the cerebellar white matter.</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">JC virus encephalopathy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>JC virus infection can result in a novel gray matter syndrome characterized by encephalopathy. A case report describes a patient who developed aphasia and progressive cognitive decline in the absence of focal neurologic deficits after chemotherapy for non-small cell lung cancer [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/79\" class=\"abstract_t\">79</a>]. The course was rapidly fatal. Polymerase chain reaction detected JC virus in cerebrospinal fluid and brain biopsy tissue. Neuropathologic examination showed focal areas of cell loss in the cortex and limited demyelination. JC virus infection of enlarged cortical pyramidal neurons was confirmed by immunostaining and electron microscopy.</p><p class=\"headingAnchor\" id=\"H89933339\"><span class=\"h2\">JC virus meningitis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>JC virus may cause meningitis and hydrocephalus, as described in a case report of a woman, age 67 years and seronegative for HIV, who presented with a two-month course characterized by headache, urinary incontinence, leg weakness, and lethargy [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/80\" class=\"abstract_t\">80</a>]. Brain imaging showed ventricular dilation but no parenchymal lesion and no meningeal enhancement. Cerebrospinal fluid analyses revealed a peak white blood cell count of 10 per mm<sup>3</sup>, elevated protein, and a very high JC viral load. She developed pancytopenia and died 5.5 months after symptom onset. Postmortem examination revealed productive JC virus infection of leptomeningeal and choroid plexus cells, and limited parenchymal involvement.</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In patients with compatible clinical and neuroimaging features, the diagnosis of progressive multifocal leukoencephalopathy (PML) is established by demonstrating the presence of JC virus DNA in the cerebrospinal fluid (CSF) using polymerase chain reaction (PCR) [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/81\" class=\"abstract_t\">81</a>]. However, brain biopsy remains the gold standard for the diagnosis. For patients with clinical and neuroimaging features of PML who have a negative PCR for JC virus in the CSF, our suggested approach is to evaluate for other neurologic disorders (see <a href=\"#H11\" class=\"local\">'Differential diagnosis'</a> below) and repeat the PCR for CSF JC virus (<a href=\"image.htm?imageKey=NEURO%2F90129\" class=\"graphic graphic_algorithm graphicRef90129 \">algorithm 1</a>). Brain biopsy is indicated if this evaluation and repeat PCR is unrevealing. Of note, retrospective data suggests that diagnostic delay is common for patients with PML [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/82\" class=\"abstract_t\">82</a>].</p><p class=\"headingAnchor\" id=\"H117387201\"><span class=\"h2\">Brain biopsy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The gold standard for diagnosis of PML is the brain biopsy. Histological examination of PML lesions reveals single or multiple areas of demyelination with the following features (<a href=\"image.htm?imageKey=NEURO%2F90142\" class=\"graphic graphic_figure graphicRef90142 \">figure 1</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>JC virus-infected oligodendrocytes with enlarged amphophilic nuclei located at the periphery of the lesions</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Reactive gliosis with enlarged, bizarre astrocytes, some sustaining a restrictive, nonlytic JC virus infection</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Macrophages containing phagocytosed myelin and cellular debris</p><p/><p>The typical histopathologic triad of PML (demyelination, bizarre astrocytes, and enlarged oligodendroglial nuclei) is not observed in other neurologic disorders [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/81\" class=\"abstract_t\">81</a>]. The presence of JC virus-infected glial cells should be confirmed by immunohistochemistry for polyomavirus proteins, or in situ hybridization for JC virus DNA. Antibodies used for immunohistochemistry are generally raised against the simian virus 40, a polyomavirus endemic in monkeys that cross reacts with JC virus.</p><p>PML lesions are usually devoid of inflammatory infiltrates. In the context of an immune reconstitution inflammatory syndrome (IRIS), active inflammatory changes may be present, including intraparenchymal and perivascular CD8+ T-lymphocyte infiltration associated with the presence of abundant JC virus as well as areas of perivenous leukoencephalitis devoid of JC virus [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/72\" class=\"abstract_t\">72</a>].</p><p>Brain biopsy has a sensitivity of 64 to 96 percent and a specificity of 100 percent for the diagnosis of PML [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/83\" class=\"abstract_t\">83</a>]. However, the risk of morbidity and mortality associated with brain biopsy in patients with HIV infection is estimated to be 8.4 and 2.9 percent, respectively [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/84\" class=\"abstract_t\">84</a>]. Furthermore, some patients may not be able to tolerate brain biopsy, or lesions may be inaccessible. As an alternative to brain biopsy, the diagnosis of PML can be established by PCR detection of JC virus DNA in the CSF in patients with appropriate neurologic and neuroradiologic features.</p><p class=\"headingAnchor\" id=\"H117387207\"><span class=\"h2\">Polymerase chain reaction</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>JC virus PCR for the diagnosis of PML had a sensitivity of 72 to 92 percent and specificity of 92 to 100 percent before the combined antiretroviral therapy (ART) era [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/85\" class=\"abstract_t\">85</a>]. However, it is now common to find negative CSF JC virus PCR results in patients with AIDS who have clinical presentation indistinguishable from PML [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/86\" class=\"abstract_t\">86</a>]. A plausible explanation for this discrepancy is that ART-induced recovery of the immune system leads to decreased viral replication and clearance of JC virus DNA from CSF [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/87\" class=\"abstract_t\">87</a>]. Based on a consensus for PML diagnostic certainty [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/81,88\" class=\"abstract_t\">81,88</a>], these patients should be considered as &quot;possible PML&quot; cases and managed accordingly, after appropriate exclusion of other neurologic conditions such as primary central nervous system lymphoma, HIV encephalopathy, and toxoplasmosis.</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In patients with HIV infection, the differential diagnosis of progressive multifocal leukoencephalopathy (PML) includes HIV encephalopathy and primary central nervous system lymphoma. Whereas PML lesions are usually asymmetric, distributed throughout the white matter, well demarcated, and associated with focal neurologic deficits, the lesions of HIV are more likely to be symmetrical, poorly demarcated, and located in the periventricular areas; they may be associated with cognitive problems and an elevated HIV viral load in the cerebrospinal fluid (CSF), but not with focal sensory, motor, or visual deficits.</p><p>Primary central nervous system (CNS) lymphoma may also mimic PML lesions. However, cortical involvement, moderate edema, diffuse post-contrast enhancement patterns, and positive CSF cytology or polymerase chain reaction for Epstein-Barr virus should help differentiate these entities. The radiological presentation of these disorders in patients with HIV infection is covered in greater detail elsewhere. (See <a href=\"topic.htm?path=approach-to-hiv-infected-patients-with-central-nervous-system-lesions\" class=\"medical medical_review\">&quot;Approach to HIV-infected patients with central nervous system lesions&quot;</a>.)</p><p>In patients without HIV infection, PML may be initially mistaken for a stroke [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/25\" class=\"abstract_t\">25</a>] or brain tumor [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/89\" class=\"abstract_t\">89</a>]. However, clinical suspicion for PML should be heightened if the neuroimaging features are those of a multifocal process limited to the white matter that does not conform to vascular territories and exhibits neither mass effect nor contrast enhancement.</p><p>Other disorders to consider in the differential of PML include the following [<a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/81\" class=\"abstract_t\">81</a>]: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>CNS vasculitis (see <a href=\"topic.htm?path=primary-angiitis-of-the-central-nervous-system-in-adults\" class=\"medical medical_review\">&quot;Primary angiitis of the central nervous system in adults&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Reversible posterior leukoencephalopathy (see <a href=\"topic.htm?path=reversible-posterior-leukoencephalopathy-syndrome\" class=\"medical medical_review\">&quot;Reversible posterior leukoencephalopathy syndrome&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Varicella-zoster virus encephalopathy (see <a href=\"topic.htm?path=clinical-manifestations-of-varicella-zoster-virus-infection-herpes-zoster#H20\" class=\"medical medical_review\">&quot;Clinical manifestations of varicella-zoster virus infection: Herpes zoster&quot;, section on 'Encephalitis'</a>)</p><p/><p>In patients with multiple sclerosis (MS), particularly those being treated with <a href=\"topic.htm?path=natalizumab-drug-information\" class=\"drug drug_general\">natalizumab</a>, who are at increased risk for PML, it may be difficult to distinguish recurrent attacks of MS from PML based upon clinical and radiologic findings. However, certain neuroimaging features may be useful in this regard:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>PML lesions may be unifocal, predominantly affect the frontal lobes (but can affect posterior brain regions), typically occur at the gray-white junction, and may be large; MS lesions are often multifocal, predominantly affect the periventricular regions, and are usually small.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>MS lesions usually have an ovoid appearance, and are oriented perpendicular to the corpus callosum and ventricular surface (Dawson finger pattern); PML lesions do not follow this pattern.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>PML lesions may be hyperintense on diffusion-weighted MRI sequences (<a href=\"image.htm?imageKey=NEURO%2F65187\" class=\"graphic graphic_diagnosticimage graphicRef65187 \">image 2</a>), whereas MS lesions do not exhibit diffusion-weighted signal abnormalities.</p><p/><p class=\"headingAnchor\" id=\"H13\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Progressive multifocal leukoencephalopathy (PML) is a deadly demyelinating disease of the central nervous system caused by a reactivation of the JC virus that occurs almost exclusively in immunosuppressed individuals.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>PML is a major opportunistic infection associated with HIV infection and AIDS, with a prevalence of about 5 percent. Outside of HIV infection, PML occurs rarely in patients with lymphoproliferative and myeloproliferative diseases, solid organ malignancies, granulomatous and inflammatory diseases, and organ transplant recipients. Rare cases of PML have been reported in patients treated with the immunomodulatory medication <a href=\"topic.htm?path=natalizumab-drug-information\" class=\"drug drug_general\">natalizumab</a>. (See <a href=\"#H2\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>PML typically presents with subacute neurologic deficits including altered mental status, visual symptoms such as hemianopia and diplopia, hemiparesis or monoparesis, and appendicular or gait ataxia. Seizures occur in up to 18 percent of patients. (See <a href=\"#H3\" class=\"local\">'Clinical manifestations'</a> above and <a href=\"#H4\" class=\"local\">'Classic PML'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>New onset or clinical worsening of PML may occur shortly after the initiation of combined antiretroviral therapy (ART) due to the immune reconstitution inflammatory syndrome (IRIS). (See <a href=\"#H7\" class=\"local\">'Inflammatory PML'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>JC virus granule cell neuronopathy presents with ataxia and cerebellar atrophy in patients with HIV infection who do not have obvious PML lesions in the cerebellum. (See <a href=\"#H8\" class=\"local\">'JC virus cerebellar granule cell neuronopathy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Unusual manifestations of JC virus include infection of cortical neurons causing encephalopathy and infection of leptomeningeal cells causing meningitis. (See <a href=\"#H9\" class=\"local\">'JC virus encephalopathy'</a> above and <a href=\"#H89933339\" class=\"local\">'JC virus meningitis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Clinical suspicion for PML should be heightened if neuroimaging reveals a multifocal process limited to the white matter that does not conform to vascular territories and exhibits neither mass effect nor contrast enhancement. In patients with HIV infection, the differential diagnosis of PML includes HIV encephalopathy and primary central nervous system lymphoma. (See <a href=\"#H60052309\" class=\"local\">'Neuroimaging'</a> above and <a href=\"#H11\" class=\"local\">'Differential diagnosis'</a> above and <a href=\"topic.htm?path=approach-to-hiv-infected-patients-with-central-nervous-system-lesions\" class=\"medical medical_review\">&quot;Approach to HIV-infected patients with central nervous system lesions&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Brain biopsy is the gold standard for diagnosis of PML but is associated with clinically significant morbidity and mortality. In patients with appropriate neurologic and neuroradiologic features, the diagnosis of PML can usually be established by polymerase chain reaction detection of JC virus DNA in the cerebrospinal fluid if brain biopsy is not desired. However, the sensitivity of polymerase chain reaction for the diagnosis of PML in patients with HIV infection appears to be declining since the advent of combined ART therapy. (See <a href=\"#H10\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The differential diagnosis of PML includes HIV encephalopathy, primary central nervous system lymphoma, primary angiitis of the central nervous system, reversible posterior leukoencephalopathy, varicella-zoster virus encephalopathy, and new or recurrent attacks of multiple sclerosis. (See <a href=\"#H11\" class=\"local\">'Differential diagnosis'</a> above.)</p><p/><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/1\" class=\"nounderline abstract_t\">ASTROM KE, MANCALL EL, RICHARDSON EP Jr. Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. Brain 1958; 81:93.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/2\" class=\"nounderline abstract_t\">Padgett BL, Walker DL, ZuRhein GM, et al. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1971; 1:1257.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/3\" class=\"nounderline abstract_t\">Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 2010; 9:425.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/4\" class=\"nounderline abstract_t\">Weber T, Trebst C, Frye S, et al. Analysis of the systemic and intrathecal humoral immune response in progressive multifocal leukoencephalopathy. J Infect Dis 1997; 176:250.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/5\" class=\"nounderline abstract_t\">Rockwell D, Ruben FL, Winkelstein A, Mendelow H. Absence of imune deficiencies in a case of progressive multifocal leukoencephalopathy. Am J Med 1976; 61:433.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/6\" class=\"nounderline abstract_t\">Bolton CF, Rozdilsky B. Primary progressive multifocal leukoencephalopathy. A case report. Neurology 1971; 21:72.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/7\" class=\"nounderline abstract_t\">Fermaglich J, Hardman JM, Earle KM. Spontaneous progressive multifocal leukoencephalopathy. Neurology 1970; 20:479.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/8\" class=\"nounderline abstract_t\">Aquino K, Koralnik IJ, Silvers D. Clinical Reasoning: An 83-year-old woman with progressive hemiataxia, tremor, and infratentorial lesions. Neurology 2011; 77:e7.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/9\" class=\"nounderline abstract_t\">Tan IL, Koralnik IJ, Rumbaugh JA, et al. Progressive multifocal leukoencephalopathy in a patient without immunodeficiency. Neurology 2011; 77:297.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/10\" class=\"nounderline abstract_t\">Gheuens S, Pierone G, Peeters P, Koralnik IJ. Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression. J Neurol Neurosurg Psychiatry 2010; 81:247.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/11\" class=\"nounderline abstract_t\">Koralnik IJ. Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name? Ann Neurol 2006; 60:162.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/12\" class=\"nounderline abstract_t\">Garc&iacute;a-Su&aacute;rez J, de Miguel D, Krsnik I, et al. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies. Am J Hematol 2005; 80:271.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/13\" class=\"nounderline abstract_t\">Gonzalez H, Bolgert F, Camporo P, Leblond V. Progressive multifocal leukoencephalitis (PML) in three patients treated with standard-dose fludarabine (FAMP). Hematol Cell Ther 1999; 41:183.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/14\" class=\"nounderline abstract_t\">Vidarsson B, Mosher DF, Salamat MS, et al. Progressive multifocal leukoencephalopathy after fludarabine therapy for low-grade lymphoproliferative disease. Am J Hematol 2002; 70:51.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/15\" class=\"nounderline abstract_t\">Saumoy M, Castells G, Escoda L, et al. Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia after treatment with fludarabine. Leuk Lymphoma 2002; 43:433.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/16\" class=\"nounderline abstract_t\">Cid J, Revilla M, Cervera A, et al. Progressive multifocal leukoencephalopathy following oral fludarabine treatment of chronic lymphocytic leukemia. Ann Hematol 2000; 79:392.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/17\" class=\"nounderline abstract_t\">McGuire JL, Fridman V, W&uuml;thrich C, et al. Progressive multifocal leukoencephalopathy associated with isolated CD8+ T-lymphocyte deficiency mimicking tumefactive MS. J Neurovirol 2011; 17:500.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/18\" class=\"nounderline abstract_t\">Power C, Gladden JG, Halliday W, et al. AIDS- and non-AIDS-related PML association with distinct p53 polymorphism. Neurology 2000; 54:743.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/19\" class=\"nounderline abstract_t\">Martinez AJ, Ahdab-Barmada M. The neuropathology of liver transplantation: comparison of main complications in children and adults. Mod Pathol 1993; 6:25.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/20\" class=\"nounderline abstract_t\">Mateen FJ, Muralidharan R, Carone M, et al. Progressive multifocal leukoencephalopathy in transplant recipients. Ann Neurol 2011; 70:305.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/21\" class=\"nounderline abstract_t\">Amend KL, Turnbull B, Foskett N, et al. Incidence of progressive multifocal leukoencephalopathy in patients without HIV. Neurology 2010; 75:1326.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/22\" class=\"nounderline abstract_t\">Holman RC, Janssen RS, Buehler JW, et al. Epidemiology of progressive multifocal leukoencephalopathy in the United States: analysis of national mortality and AIDS surveillance data. Neurology 1991; 41:1733.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/23\" class=\"nounderline abstract_t\">Levy RM, Bredesen DE, Rosenblum ML. Neurological manifestations of the acquired immunodeficiency syndrome (AIDS): experience at UCSF and review of the literature. J Neurosurg 1985; 62:475.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/24\" class=\"nounderline abstract_t\">Berger JR, Kaszovitz B, Post MJ, Dickinson G. Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. A review of the literature with a report of sixteen cases. Ann Intern Med 1987; 107:78.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/25\" class=\"nounderline abstract_t\">Koralnik IJ, Schellingerhout D, Frosch MP. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 14-2004. A 66-year-old man with progressive neurologic deficits. N Engl J Med 2004; 350:1882.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/26\" class=\"nounderline abstract_t\">Berger JR, Scott G, Albrecht J, et al. Progressive multifocal leukoencephalopathy in HIV-1-infected children. AIDS 1992; 6:837.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/27\" class=\"nounderline abstract_t\">Vandersteenhoven JJ, Dbaibo G, Boyko OB, et al. Progressive multifocal leukoencephalopathy in pediatric acquired immunodeficiency syndrome. Pediatr Infect Dis J 1992; 11:232.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/28\" class=\"nounderline abstract_t\">Dankner WM, Lindsey JC, Levin MJ, Pediatric AIDS Clinical Trials Group Protocol Teams 051, 128, 138, 144, 152, 179, 190, 220, 240, 245, 254, 300 and 327. Correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretroviral therapy. Pediatr Infect Dis J 2001; 20:40.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/29\" class=\"nounderline abstract_t\">Haider S, Nafziger D, Gutierrez JA, et al. Progressive multifocal leukoencephalopathy and idiopathic CD4+lymphocytopenia: a case report and review of reported cases. Clin Infect Dis 2000; 31:E20.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/30\" class=\"nounderline abstract_t\">Sacktor N. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol 2002; 8 Suppl 2:115.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/31\" class=\"nounderline abstract_t\">Engsig FN, Hansen AB, Omland LH, et al. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect Dis 2009; 199:77.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/32\" class=\"nounderline abstract_t\">Shankar SK, Satishchandra P, Mahadevan A, et al. Low prevalence of progressive multifocal leukoencephalopathy in India and Africa: is there a biological explanation? J Neurovirol 2003; 9 Suppl 1:59.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/33\" class=\"nounderline abstract_t\">Siddiqi OK, Ghebremichael M, Dang X, et al. Molecular diagnosis of central nervous system opportunistic infections in HIV-infected Zambian adults. Clin Infect Dis 2014; 58:1771.</a></li><li class=\"breakAll\">Nulojix (belatacept): Risk Evaluation and Mitigation Strategy (REMS). Increased risk of post-transplant lymphoproliferative disorder (PTLD), predominantly involving the central nervous system (CNS), and progressive multifocal leukoencephalopathy (PML). www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm262210.htm (Accessed on July 07, 2011).</li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/35\" class=\"nounderline abstract_t\">Griny&oacute; J, Charpentier B, Pestana JM, et al. An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation 2010; 90:1521.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/36\" class=\"nounderline abstract_t\">von Geldern G, Pardo CA, Calabresi PA, Newsome SD. PML-IRIS in a patient treated with brentuximab. Neurology 2012; 79:2075.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/37\" class=\"nounderline abstract_t\">G&oacute;mez-Cibeira E, Ivanovic-Barbeito Y, Guti&eacute;rrez-Mart&iacute;nez E, et al. Eculizumab-related progressive multifocal leukoencephalopathy. Neurology 2016; 86:399.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/38\" class=\"nounderline abstract_t\">Talamonti M, Spallone G, Di Stefani A, et al. Efalizumab. Expert Opin Drug Saf 2011; 10:239.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/39\" class=\"nounderline abstract_t\">Kothary N, Diak IL, Brinker A, et al. Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. J Am Acad Dermatol 2011; 65:546.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/40\" class=\"nounderline abstract_t\">Newton P, Aldridge RD, Lessells AM, Best PV. Progressive multifocal leukoencephalopathy complicating systemic lupus erythematosus. Arthritis Rheum 1986; 29:337.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/41\" class=\"nounderline abstract_t\">Raisch DW, Rafi JA, Chen C, Bennett CL. Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system. Expert Opin Drug Saf 2016; 15:1003.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/42\" class=\"nounderline abstract_t\">Lutz M, Schulze AB, Rebber E, et al. Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia. Cancer Res Treat 2017; 49:548.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/43\" class=\"nounderline abstract_t\">Kumar D, Bouldin TW, Berger RG. A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab. Arthritis Rheum 2010; 62:3191.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/44\" class=\"nounderline abstract_t\">Neff RT, Hurst FP, Falta EM, et al. Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation. Transplantation 2008; 86:1474.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/45\" class=\"nounderline abstract_t\">Manfro RC, Vedolin L, Cantarelli M, et al. Progressive multifocal leukoencephalopathy in a kidney transplant recipient after conversion to mycophenolic acid therapy. Transpl Infect Dis 2009; 11:189.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/46\" class=\"nounderline abstract_t\">Pavlovic AM, Bonaci-Nikolic B, Kozic D, et al. Progressive multifocal leukoencephalopathy associated with mycophenolate mofetil treatment in a woman with lupus and CD4+ T-lymphocyte deficiency. Lupus 2012; 21:100.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/47\" class=\"nounderline abstract_t\">Goldberg SL, Pecora AL, Alter RS, et al. Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 2002; 99:1486.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/48\" class=\"nounderline abstract_t\">Calabrese LH, Molloy ES, Huang D, Ransohoff RM. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum 2007; 56:2116.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/49\" class=\"nounderline abstract_t\">Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113:4834.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/50\" class=\"nounderline abstract_t\">Wathes R, Moule S, Milojkovic D. Progressive multifocal leukoencephalopathy associated with ruxolitinib. N Engl J Med 2013; 369:197.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/51\" class=\"nounderline abstract_t\">Warnatz K, Peter HH, Schumacher M, et al. Infectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literature. Ann Rheum Dis 2003; 62:50.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/52\" class=\"nounderline abstract_t\">Bernal-Cano F, Joseph JT, Koralnik IJ. Spinal cord lesions of progressive multifocal leukoencephalopathy in an acquired immunodeficiency syndrome patient. J Neurovirol 2007; 13:474.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/53\" class=\"nounderline abstract_t\">Lima MA, Drislane FW, Koralnik IJ. Seizures and their outcome in progressive multifocal leukoencephalopathy. Neurology 2006; 66:262.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/54\" class=\"nounderline abstract_t\">Miskin DP, Herman ST, Ngo LH, Koralnik IJ. Predictors and characteristics of seizures in survivors of progressive multifocal leukoencephalopathy. J Neurovirol 2016; 22:464.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/55\" class=\"nounderline abstract_t\">Whiteman ML, Post MJ, Berger JR, et al. Progressive multifocal leukoencephalopathy in 47 HIV-seropositive patients: neuroimaging with clinical and pathologic correlation. Radiology 1993; 187:233.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/56\" class=\"nounderline abstract_t\">Skiest DJ. Focal neurological disease in patients with acquired immunodeficiency syndrome. Clin Infect Dis 2002; 34:103.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/57\" class=\"nounderline abstract_t\">Sahraian MA, Radue EW, Eshaghi A, et al. Progressive multifocal leukoencephalopathy: a review of the neuroimaging features and differential diagnosis. Eur J Neurol 2012; 19:1060.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/58\" class=\"nounderline abstract_t\">Bergui M, Bradac GB, Oguz KK, et al. Progressive multifocal leukoencephalopathy: diffusion-weighted imaging and pathological correlations. Neuroradiology 2004; 46:22.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/59\" class=\"nounderline abstract_t\">K&uuml;ker W, Mader I, N&auml;gele T, et al. Progressive multifocal leukoencephalopathy: value of diffusion-weighted and contrast-enhanced magnetic resonance imaging for diagnosis and treatment control. Eur J Neurol 2006; 13:819.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/60\" class=\"nounderline abstract_t\">Post MJ, Yiannoutsos C, Simpson D, et al. Progressive multifocal leukoencephalopathy in AIDS: are there any MR findings useful to patient management and predictive of patient survival? AIDS Clinical Trials Group, 243 Team. AJNR Am J Neuroradiol 1999; 20:1896.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/61\" class=\"nounderline abstract_t\">Lassmann H, Lucchinetti CF. Cortical demyelination in CNS inflammatory demyelinating diseases. Neurology 2008; 70:332.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/62\" class=\"nounderline abstract_t\">Du Pasquier RA, Koralnik IJ. Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial? J Neurovirol 2003; 9 Suppl 1:25.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/63\" class=\"nounderline abstract_t\">Koralnik IJ. New insights into progressive multifocal leukoencephalopathy. Curr Opin Neurol 2004; 17:365.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/64\" class=\"nounderline abstract_t\">Huang D, Cossoy M, Li M, et al. Inflammatory progressive multifocal leukoencephalopathy in human immunodeficiency virus-negative patients. Ann Neurol 2007; 62:34.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/65\" class=\"nounderline abstract_t\">Yousry TA, Pelletier D, Cadavid D, et al. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2012; 72:779.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/66\" class=\"nounderline abstract_t\">Arnaud FX, Hissene A, M&eacute;tivier D, et al. Gadolinium enhancement in brain magnetic resonance imaging in progressive multifocal leukoencephalopathy after natalizumab monotherapy: is it really atypical? J Neuroradiol 2012; 39:267.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/67\" class=\"nounderline abstract_t\">Moll NM, Rietsch AM, Ransohoff AJ, et al. Cortical demyelination in PML and MS: Similarities and differences. Neurology 2008; 70:336.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/68\" class=\"nounderline abstract_t\">W&uuml;thrich C, Koralnik IJ. Frequent infection of cortical neurons by JC virus in patients with progressive multifocal leukoencephalopathy. J Neuropathol Exp Neurol 2012; 71:54.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/69\" class=\"nounderline abstract_t\">Tan IL, McArthur JC, Clifford DB, et al. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology 2011; 77:1061.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/70\" class=\"nounderline abstract_t\">Gheuens S, Smith DR, Wang X, et al. Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS. Neurology 2012; 78:1390.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/71\" class=\"nounderline abstract_t\">Vermersch P, Kappos L, Gold R, et al. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology 2011; 76:1697.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/72\" class=\"nounderline abstract_t\">Vendrely A, Bienvenu B, Gasnault J, et al. Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy. Acta Neuropathol 2005; 109:449.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/73\" class=\"nounderline abstract_t\">Tan K, Roda R, Ostrow L, et al. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology 2009; 72:1458.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/74\" class=\"nounderline abstract_t\">Du Pasquier RA, Corey S, Margolin DH, et al. Productive infection of cerebellar granule cell neurons by JC virus in an HIV+ individual. Neurology 2003; 61:775.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/75\" class=\"nounderline abstract_t\">Koralnik IJ, W&uuml;thrich C, Dang X, et al. JC virus granule cell neuronopathy: A novel clinical syndrome distinct from progressive multifocal leukoencephalopathy. Ann Neurol 2005; 57:576.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/76\" class=\"nounderline abstract_t\">W&uuml;thrich C, Cheng YM, Joseph JT, et al. Frequent infection of cerebellar granule cell neurons by polyomavirus JC in progressive multifocal leukoencephalopathy. J Neuropathol Exp Neurol 2009; 68:15.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/77\" class=\"nounderline abstract_t\">Dang X, Vidal JE, Oliveira AC, et al. JC virus granule cell neuronopathy is associated with VP1 C terminus mutants. J Gen Virol 2012; 93:175.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/78\" class=\"nounderline abstract_t\">Agnihotri SP, Dang X, Carter JL, et al. JCV GCN in a natalizumab-treated MS patient is associated with mutations of the VP1 capsid gene. Neurology 2014; 83:727.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/79\" class=\"nounderline abstract_t\">W&uuml;thrich C, Dang X, Westmoreland S, et al. Fulminant JC virus encephalopathy with productive infection of cortical pyramidal neurons. Ann Neurol 2009; 65:742.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/80\" class=\"nounderline abstract_t\">Agnihotri SP, Wuthrich C, Dang X, et al. A fatal case of JC virus meningitis presenting with hydrocephalus in a human immunodeficiency virus-seronegative patient. Ann Neurol 2014; 76:140.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/81\" class=\"nounderline abstract_t\">Berger JR, Aksamit AJ, Clifford DB, et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology 2013; 80:1430.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/82\" class=\"nounderline abstract_t\">Miskin DP, Ngo LH, Koralnik IJ. Diagnostic delay in progressive multifocal leukoencephalopathy. Ann Clin Transl Neurol 2016; 3:386.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/83\" class=\"nounderline abstract_t\">Koralnik IJ, Boden D, Mai VX, et al. JC virus DNA load in patients with and without progressive multifocal leukoencephalopathy. Neurology 1999; 52:253.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/84\" class=\"nounderline abstract_t\">Skolasky RL, Dal Pan GJ, Olivi A, et al. HIV-associated primary CNS lymorbidity and utility of brain biopsy. J Neurol Sci 1999; 163:32.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/85\" class=\"nounderline abstract_t\">Cinque P, Scarpellini P, Vago L, et al. Diagnosis of central nervous system complications in HIV-infected patients: cerebrospinal fluid analysis by the polymerase chain reaction. AIDS 1997; 11:1.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/86\" class=\"nounderline abstract_t\">Marzocchetti A, Di Giambenedetto S, Cingolani A, et al. Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy. J Clin Microbiol 2005; 43:4175.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/87\" class=\"nounderline abstract_t\">Cinque P, Bossolasco S, Lundkvist A. Molecular analysis of cerebrospinal fluid in viral diseases of the central nervous system. J Clin Virol 2003; 26:1.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/88\" class=\"nounderline abstract_t\">Cinque P, Koralnik IJ, Clifford DB. The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy: defining a consensus terminology. J Neurovirol 2003; 9 Suppl 1:88.</a></li><li><a href=\"https://www.uptodate.com/contents/progressive-multifocal-leukoencephalopathy-epidemiology-clinical-manifestations-and-diagnosis/abstract/89\" class=\"nounderline abstract_t\">Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005; 353:362.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 1694 Version 18.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H13\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">EPIDEMIOLOGY</a><ul><li><a href=\"#H3055033646\" id=\"outline-link-H3055033646\">Immunomodulatory drugs and PML</a></li></ul></li><li><a href=\"#H3\" id=\"outline-link-H3\">CLINICAL MANIFESTATIONS</a><ul><li><a href=\"#H4\" id=\"outline-link-H4\">Classic PML</a><ul><li><a href=\"#H60052309\" id=\"outline-link-H60052309\">- Neuroimaging</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">- Neuropathology</a></li></ul></li><li><a href=\"#H7\" id=\"outline-link-H7\">Inflammatory PML</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">JC virus cerebellar granule cell neuronopathy</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">JC virus encephalopathy</a></li><li><a href=\"#H89933339\" id=\"outline-link-H89933339\">JC virus meningitis</a></li></ul></li><li><a href=\"#H10\" id=\"outline-link-H10\">DIAGNOSIS</a><ul><li><a href=\"#H117387201\" id=\"outline-link-H117387201\">Brain biopsy</a></li><li><a href=\"#H117387207\" id=\"outline-link-H117387207\">Polymerase chain reaction</a></li></ul></li><li><a href=\"#H11\" id=\"outline-link-H11\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"NEURO/1694|ALG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"ALGORITHMS\">ALGORITHMS</a></div><ul><li><a href=\"image.htm?imageKey=NEURO/90129\" class=\"graphic graphic_algorithm\">- Algorithm for diagnosing PML</a></li></ul></li><li><div id=\"NEURO/1694|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=NEURO/72702\" class=\"graphic graphic_diagnosticimage\">- Brain MRI of PML in HIV infection</a></li><li><a href=\"image.htm?imageKey=NEURO/65187\" class=\"graphic graphic_diagnosticimage\">- PML after organ transplantation</a></li></ul></li><li><div id=\"NEURO/1694|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=NEURO/90142\" class=\"graphic graphic_figure\">- Pathology of PML</a></li><li><a href=\"image.htm?imageKey=NEURO/67660\" class=\"graphic graphic_figure\">- JC virus granule cell neuronopathy in PML</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-hiv-infected-patients-with-central-nervous-system-lesions\" class=\"medical medical_review\">Approach to HIV-infected patients with central nervous system lesions</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-of-varicella-zoster-virus-infection-herpes-zoster\" class=\"medical medical_review\">Clinical manifestations of varicella-zoster virus infection: Herpes zoster</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=idiopathic-cd4-lymphocytopenia\" class=\"medical medical_review\">Idiopathic CD4+ lymphocytopenia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=immune-reconstitution-inflammatory-syndrome\" class=\"medical medical_review\">Immune reconstitution inflammatory syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=natalizumab-for-relapsing-remitting-multiple-sclerosis-in-adults\" class=\"medical medical_review\">Natalizumab for relapsing-remitting multiple sclerosis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=natalizumab-for-treatment-of-crohn-disease-in-adults\" class=\"medical medical_review\">Natalizumab for treatment of Crohn disease in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=primary-angiitis-of-the-central-nervous-system-in-adults\" class=\"medical medical_review\">Primary angiitis of the central nervous system in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=progressive-multifocal-leukoencephalopathy-treatment-and-prognosis\" class=\"medical medical_review\">Progressive multifocal leukoencephalopathy: Treatment and prognosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=reversible-posterior-leukoencephalopathy-syndrome\" class=\"medical medical_review\">Reversible posterior leukoencephalopathy syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=virology-epidemiology-and-pathogenesis-of-jc-polyomavirus-bk-polyomavirus-and-other-human-polyomaviruses\" class=\"medical medical_review\">Virology, epidemiology, and pathogenesis of JC polyomavirus, BK polyomavirus, and other human polyomaviruses</a></li></ul></div></div>","javascript":null}